SLCO1B1 Genetic Test: Statin Muscle Risk, Simvastatin, and Results

An SLCO1B1 genetic test looks for inherited variants that can reduce the liver’s uptake of certain statins, especially simvastatin. When that transport is reduced, more active statin may remain in the bloodstream, increasing exposure in muscle and the chance of statin-associated muscle symptoms. The best-studied variant is SLCO1B1 c.521T>C, also called rs4149056. A result may be reported as a genotype, a pair of star alleles, or an OATP1B1 function category such as normal, decreased, or poor function. The test does not show whether a person currently has muscle injury, and it cannot predict symptoms with certainty. Instead, it adds one piece of information to the choice of statin, dose, monitoring plan, and review of other risk factors. Its clinical value is strongest when simvastatin is being considered, when muscle symptoms have complicated treatment, or when a result is already available from a broader pharmacogenetic panel.

• Main purpose: Estimate genetically influenced statin exposure and muscle-risk, with the clearest evidence for simvastatin.
• Key variant: SLCO1B1 c.521T>C can reduce OATP1B1 transporter function.
• Result meaning: Decreased or poor function raises risk but does not prove that muscle symptoms will occur.
• Clinical response: A clinician may select another statin, use a lower dose, or monitor more closely rather than abandoning cholesterol treatment.
• Important limitation: Dose, drug interactions, age, kidney or liver disease, thyroid status, exercise, and other conditions may matter as much as genotype.

Table of Contents

• What the SLCO1B1 Test Measures
• How SLCO1B1 Affects Simvastatin
• Who May Benefit From Testing
• How the Test Is Performed
• Understanding SLCO1B1 Results
• Using Results to Guide Statin Therapy
• Muscle Symptoms and Other Risk Factors
• Limits, Costs, and Next Steps

What the SLCO1B1 Test Measures

The SLCO1B1 gene provides instructions for making organic anion transporting polypeptide 1B1, usually shortened to OATP1B1. This transporter sits on the surface of liver cells and helps move several medicines and naturally occurring compounds from the blood into the liver. That movement is important because the liver is both the main site where statins act and a major site where they are processed or cleared.

A genetic test examines selected DNA variants in SLCO1B1. The variant most often tested is c.521T>C, identified in databases as rs4149056. The C version reduces transporter activity. A person inherits one SLCO1B1 copy from each biological parent, so the laboratory may report TT, TC, or CC at this position. Some reports use CT rather than TC; they mean the same pair of variants.

Other laboratories report star alleles, such as *1, *5, *15, or *37. Star alleles describe combinations of variants inherited together. The two star alleles form a diplotype, which is translated into a predicted transporter phenotype. Current reports may use categories such as:

• Normal function: Both inherited alleles are expected to support usual or near-usual transport.
• Decreased function: Overall transport is expected to be lower than normal, often because one allele has reduced function.
• Poor function: Transport is expected to be substantially reduced, often because both alleles have reduced or no function.
• Indeterminate or uncertain: The laboratory cannot confidently assign function from the variants detected.

Terminology can differ among laboratories and may change as allele definitions are updated. The clinically useful part is not merely the letters on the report but the laboratory’s genotype-to-phenotype translation, the variants included in the assay, and the medication-specific recommendation.

SLCO1B1 testing is pharmacogenetic, not diagnostic. It is designed to inform medication decisions. It does not diagnose high cholesterol, coronary artery disease, muscle disease, or statin intolerance. It also does not measure cholesterol response directly. A pharmacogenetic test estimates how inherited variation may influence drug handling; lipid levels and treatment response still require ordinary clinical testing.

How SLCO1B1 Affects Simvastatin

Simvastatin is taken in an inactive lactone form and converted to simvastatin acid, the active form that inhibits cholesterol production in the liver. OATP1B1 helps carry simvastatin acid from the circulation into liver cells. When transporter function is reduced, uptake into the liver is less efficient. Blood exposure to simvastatin acid may rise, leaving more drug available to reach skeletal muscle.

That mechanism explains why the SLCO1B1 association is strongest for simvastatin-associated myopathy, particularly at higher doses. Myopathy is a clinical term for muscle disease and may include muscle pain or weakness with a marked rise in creatine kinase, an enzyme released from injured muscle. Rhabdomyolysis is a rare, severe form of muscle breakdown that can damage the kidneys.

The broader phrase statin-associated muscle symptoms, or SAMS, includes a range of experiences:

• aching, soreness, cramps, stiffness, or heaviness;
• weakness or reduced exercise tolerance;
• symptoms with a normal creatine kinase level;
• myopathy with laboratory evidence of muscle injury; and
• very rarely, rhabdomyolysis.

Not every muscle symptom during statin use is caused by the statin. Muscle pain is common in the general population, and symptoms may come from exercise, arthritis, thyroid disease, vitamin deficiencies, infection, nerve disorders, inflammatory muscle disease, or another medication. SLCO1B1 genotype can strengthen or weaken suspicion in the right setting, but it cannot establish causation on its own.

The effect also differs by statin. Statins vary in how strongly they depend on OATP1B1 transport, how they are metabolized, and how much systemic exposure changes when transporter function is low. Simvastatin has the most established gene–drug relationship. Pravastatin and rosuvastatin also use hepatic transporters, but their dosing decisions are not identical. Atorvastatin risk may be influenced by SLCO1B1 along with dose, interacting drugs, and other factors. Fluvastatin and pitavastatin have their own pharmacokinetic profiles.

This is why a result should not be simplified to “all statins are unsafe.” The goal is to preserve effective cardiovascular prevention while reducing avoidable adverse effects. A person with reduced function may tolerate a different statin, a lower exposure regimen, or a carefully selected combination of lipid-lowering medicines.

Who May Benefit From Testing

Routine SLCO1B1 testing is not required before every statin prescription. Clinical guidelines that explain how to use a result do not necessarily recommend that everyone be tested. Testing is most useful when the answer could change a real prescribing decision.

A clinician may consider testing when:

• simvastatin is being considered and a higher muscle-risk would change the drug or dose;
• a person has had unexplained muscle symptoms on one or more statins;
• previous symptoms led to repeated discontinuation, leaving cholesterol undertreated;
• a pharmacogenetic panel has already produced an SLCO1B1 result;
• there are several non-genetic risk factors for high statin exposure;
• long-term therapy is expected and avoiding a preventable trial-and-error cycle has value; or
• a health system uses preemptive pharmacogenetic testing with clinical decision support.

Testing may be less helpful when the treatment choice is already clear. For example, if a person has tolerated an effective statin dose for years without symptoms, a newly discovered decreased-function result does not automatically require a change. Similarly, if simvastatin will not be used and the clinician has already chosen a statin and dose with low concern for this gene–drug interaction, testing may add little.

People with cardiovascular disease, diabetes, familial hypercholesterolemia, or high estimated cardiovascular risk often gain substantial benefit from lowering LDL cholesterol. A genetic result should be used to help find a sustainable therapy, not as a reason to leave serious risk untreated. Stopping a statin without a replacement plan can increase preventable heart attack and stroke risk.

Testing can also be relevant after a prior label of “statin intolerance.” That label should be reviewed carefully. The timing of symptoms, response to stopping and restarting, statin type, dose, interacting medicines, creatine kinase, thyroid function, and alternative explanations all matter. An SLCO1B1 result may support selection of a different regimen, but normal function does not invalidate a person’s symptoms. Many cases of genuine intolerance arise through mechanisms not captured by this single gene.

Family members do not usually need testing merely because one relative has an SLCO1B1 variant. The result is inherited, but it is not a disease mutation in the usual sense. Testing another person is most relevant when that individual has a medication decision of their own.

How the Test Is Performed

SLCO1B1 testing usually requires a cheek swab, saliva sample, or small blood sample. The laboratory extracts DNA and examines one or more predefined variants. Some tests analyze only c.521T>C. Others include several SLCO1B1 variants and assign star alleles. Broader panels may test SLCO1B1 together with genes that influence antidepressants, pain medicines, blood thinners, transplant drugs, and other therapies.

The steps are generally straightforward:

1. A clinician or authorized service orders the test.
2. The sample is collected according to the laboratory’s instructions.
3. DNA is analyzed using targeted genotyping, an array, or sequencing.
4. The laboratory reports the detected variants or alleles.
5. Software or a specialist converts the genotype into a predicted function phenotype.
6. The result is interpreted in the context of the current or proposed statin regimen.

A high-quality report should state what was tested. This matters because a “negative” result may mean only that the limited variants on that assay were not found. Targeted testing can miss rare or newly characterized variants. Star-allele assignment can also depend on which positions were examined and whether the laboratory could determine which variants occur on the same chromosome.

Because inherited DNA usually does not change, a valid result can be useful throughout life. However, interpretation can change as evidence, allele definitions, and clinical guidelines evolve. Keeping the original laboratory report is important. A copied phenotype in a medical record may become outdated or lose details about the test’s coverage.

Turnaround time ranges from several days to a few weeks depending on the laboratory and setting. A result needed for an urgent prescription may not arrive fast enough to guide the first dose. In that situation, the clinician can select a reasonable statin using clinical factors and revisit the regimen when the result becomes available.

Direct-to-consumer or raw-data results require caution. A single data point may have uncertain quality, strand orientation, or interpretation. Medication changes should be based on a clinically validated result and reviewed by a pharmacist, prescriber, genetic counselor, or another professional familiar with pharmacogenetics. The same principle applies to SNP genotyping results obtained for general health or ancestry purposes.

Understanding SLCO1B1 Results

The report may look technical, but interpretation follows a simple chain: variant → allele or diplotype → transporter function → medication recommendation. The table below shows common result concepts. Exact labels should be taken from the testing laboratory because variant coverage and translation systems differ.

Possible report finding	Predicted OATP1B1 function	General simvastatin implication
Two normal-function alleles, often including c.521TT	Normal function	Usual genetically predicted exposure; standard prescribing may be reasonable with routine clinical monitoring
One reduced-function allele, often including c.521TC	Decreased function	Higher simvastatin exposure and muscle-risk than normal function; consider a lower-risk statin or dose
Two reduced-function alleles, often including c.521CC	Poor function	Substantially higher exposure and risk; an alternative statin is commonly favored
Rare variant, incomplete allele call, or conflicting evidence	Indeterminate or uncertain	No confident gene-based recommendation; use clinical factors and seek expert interpretation

A few distinctions prevent common misunderstandings.

Genotype is not the same as phenotype. Genotype names the DNA findings. Phenotype predicts transporter function. Two laboratories may display different levels of detail while reaching the same practical function category.

Relative risk is not absolute certainty. A decreased-function result means risk is higher compared with a reference group under similar treatment conditions. It does not mean muscle injury is inevitable. Many carriers tolerate statins, particularly when the drug and dose are selected thoughtfully.

A normal result is not a guarantee. Normal-function patients can still develop muscle symptoms because of high dose, drug interactions, illness, intense exercise, age-related changes, or mechanisms involving other genes and pathways.

The result is medication-specific. A poor-function label does not mean the liver generally “works poorly.” It describes one transporter pathway. The importance varies among medicines and even among statins.

An uncertain result is not necessarily abnormal. It may reflect limited evidence or incomplete testing rather than a harmful variant. Clinical action should not be improvised from a variant of uncertain significance.

Reports may also include separate recommendations from organizations such as the Clinical Pharmacogenetics Implementation Consortium or the Dutch Pharmacogenetics Working Group. These recommendations can differ because they evaluate evidence and health-system practice differently. A clinician should use a current guideline, the exact phenotype, the intended statin, the dose needed to reach the LDL goal, and the patient’s other risk factors.

Using Results to Guide Statin Therapy

The central treatment question is not “Can this person take a statin?” It is “Which regimen provides the needed LDL reduction with an acceptable likelihood of adverse effects?” SLCO1B1 results help answer that question most directly for simvastatin.

For normal OATP1B1 function, clinicians can generally use ordinary prescribing guidance. That still includes attention to dose limits, interacting medicines, liver and kidney status, symptoms, and the treatment goal. Normal genotype does not justify ignoring clinical warnings.

For decreased function, a clinician may avoid a high-exposure simvastatin regimen, select another statin, or use a lower dose with close follow-up. The exact choice depends on how much LDL lowering is needed. A low-intensity dose may be inadequate for someone with established cardiovascular disease, so simply reducing the dose without an alternative plan may sacrifice benefit.

For poor function, an alternative to simvastatin is commonly preferred. The clinician may choose a statin with a more favorable recommendation for that phenotype, then adjust dose based on LDL response and tolerability. The choice is not automatically the same for every patient because SLCO1B1 also affects some other statins to varying degrees.

Possible strategies include:

• changing from simvastatin to another statin;
• using a lower statin dose and titrating carefully;
• choosing a statin with different transport or metabolism characteristics;
• adding a non-statin LDL-lowering medicine when a lower statin dose is insufficient;
• correcting reversible risk factors before rechallenge;
• checking for interacting prescriptions, over-the-counter products, and supplements; and
• documenting the successful regimen so an avoidable high-risk prescription is not repeated.

Genotype-guided prescribing should remain goal-directed. LDL cholesterol is measured after treatment starts or changes, because DNA cannot show whether the selected regimen achieves the needed reduction. Adherence, diet, underlying lipid disorder, and concurrent medicines all affect the observed result.

A previous adverse experience deserves a structured rechallenge plan when clinically appropriate. The clinician may wait for symptoms to resolve, confirm that creatine kinase and other tests are acceptable, introduce a different statin at a conservative dose, and increase only as tolerated. Some patients do well with alternate dosing schedules, although such plans are individualized and not determined by SLCO1B1 alone.

The result should also be stored where future prescribers and pharmacists can find it. Pharmacogenetic data are most useful when linked to medication-order alerts that present a concise recommendation at the point of care. A PDF buried in a patient portal may not prevent a later high-risk prescription.

Muscle Symptoms and Other Risk Factors

Genetic risk interacts with the complete clinical picture. A person with normal SLCO1B1 function may have high overall risk, while a person with decreased function may remain symptom-free on a carefully chosen regimen.

Factors that can increase statin muscle-risk include:

• higher statin dose or systemic exposure;
• older age, frailty, or low body mass;
• impaired kidney or liver function;
• untreated hypothyroidism;
• a personal or family history of muscle disease;
• heavy unaccustomed exercise or recent muscle injury;
• acute infection, dehydration, or major surgery;
• interacting medicines that inhibit statin metabolism or transport;
• certain combinations, such as a statin with gemfibrozil; and
• previous muscle symptoms during statin therapy.

Medication review is especially important with simvastatin because some drugs can substantially increase its concentration. Depending on the medicine, the combination may be contraindicated, require a simvastatin dose limit, or favor another statin. The list changes as prescriptions change, so a genetic result obtained years earlier does not replace a current interaction check.

When symptoms occur, note their location, symmetry, severity, timing, and relationship to starting, stopping, or changing the statin. Typical SAMS often affects large muscle groups on both sides, but real presentations vary. Clinicians may order creatine kinase, thyroid-stimulating hormone, kidney function, liver tests, or other studies based on the presentation. A normal creatine kinase does not rule out statin-associated aches, while a very high value raises concern for significant injury.

Seek urgent medical assessment for severe or rapidly worsening weakness, profound muscle pain, dark brown urine, markedly reduced urine, fever with muscle symptoms, confusion, or symptoms after an interacting drug was added. These features can signal rhabdomyolysis or another serious condition. Do not wait for a genetic result before evaluating an acute problem.

Rarely, statin exposure is associated with immune-mediated necrotizing myopathy, in which weakness and creatine kinase elevation may persist despite stopping the statin. This is different from ordinary SAMS and requires specialist assessment. SLCO1B1 testing is not a diagnostic test for that autoimmune condition.

Patients should not discontinue cardiovascular prevention silently. Contact the prescriber promptly so symptoms can be assessed and an alternative plan made. Most people who have difficulty with one statin can eventually use another statin, a modified regimen, non-statin therapy, or a combination that achieves meaningful LDL reduction.

Limits, Costs, and Next Steps

SLCO1B1 testing has a well-supported biological basis and an actionable relationship with simvastatin, but it has important limits. It explains only part of the variation in statin exposure and muscle symptoms. It does not capture every transporter, metabolic enzyme, immune mechanism, interaction, or clinical vulnerability.

Evidence is also uneven across drugs and outcomes. The relationship is strongest for simvastatin myopathy and systemic exposure. Associations with mild muscle pain, LDL-lowering response, or other statins are less consistent. A test marketed broadly as a “statin intolerance gene” can therefore overstate what one variant can predict.

Test coverage varies. A single-variant assay may identify the common c.521T>C finding but miss other reduced-function alleles. A panel may report star alleles, yet its translation may depend on population data and evolving nomenclature. Rare variants can be difficult to classify. Laboratories should use validated methods, clear phenotype translation, and transparent limitations.

Cost ranges from relatively modest targeted testing to several hundred dollars for a broader panel. Insurance coverage differs by location, plan, diagnosis, and whether testing is considered medically necessary. Ask about laboratory charges, professional interpretation fees, and whether the result will be integrated into the medical record. A large panel is not automatically better if it adds many findings that are unrelated to the present treatment decision.

Privacy protections and consent also deserve attention. Pharmacogenetic results are inherited information. Patients should know who receives the result, whether the laboratory retains the sample, whether data may be used for research, and how results are shared. Legal protections for genetic information differ by country and may not cover every form of insurance.

After receiving a result, useful next steps are to:

1. Confirm the exact genotype, star alleles, and predicted function phenotype.
2. Verify that the report used a current medication-specific guideline.
3. Review every current medicine and supplement for interactions.
4. Discuss the LDL goal and the intensity of treatment needed.
5. Consider prior symptoms, laboratory findings, and reversible causes.
6. Agree on a statin or alternative regimen and a follow-up date.
7. Recheck lipids and symptoms after a treatment change.
8. Store the result in a durable, searchable part of the health record.

The best use of an SLCO1B1 result is practical and balanced: reduce avoidable simvastatin exposure, investigate symptoms rather than dismissing them, and maintain effective protection against cardiovascular disease. The result can guide a safer route to treatment, but it should never replace clinical evaluation or become a reason to accept uncontrolled cholesterol.

References

• The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 Genotypes and Statin-Associated Musculoskeletal Symptoms (2022, Clinical Guideline)
• Simvastatin Therapy and SLCO1B1 Genotype (2024, Medical Genetics Summary)
• Dutch Pharmacogenetics Working Group Guideline for the Gene–Drug Interaction Between SLCO1B1 and Statins and CYP2C9 and Sulfonylureas (2025, Clinical Guideline)
• SLCO1B1 Gene-Based Clinical Decision Support Reduces Statin-Associated Muscle Symptoms Risk With Simvastatin Prescribing (2023, Implementation Study)
• Table of Pharmacogenetic Associations (2022, Regulatory Resource)

Disclaimer

This article provides general educational information and is not a diagnosis, prescription, or substitute for care from a qualified clinician. Do not start, stop, or change a statin based only on a genetic result; treatment should account for cardiovascular risk, LDL goals, symptoms, other medical conditions, and drug interactions. Severe weakness, dark urine, or rapidly worsening muscle symptoms require prompt medical evaluation.